{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T05:29:26Z","timestamp":1740461366839,"version":"3.37.3"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:00:00Z","timestamp":1740355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:00:00Z","timestamp":1740355200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Fujian Provincial Health Commission Medical Innovation Research Project","award":["2023CXA051"],"award-info":[{"award-number":["2023CXA051"]}]},{"DOI":"10.13039\/100016078","name":"Fuzhou Science and Technology Bureau","doi-asserted-by":"crossref","award":["2022-S-011"],"award-info":[{"award-number":["2022-S-011"]}],"id":[{"id":"10.13039\/100016078","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-90183-0","type":"journal-article","created":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T13:17:44Z","timestamp":1740403064000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Development and validation of an Immune-related Gene-based model for predicting prognosis and immunotherapy outcomes in hepatocellular carcinoma patients"],"prefix":"10.1038","volume":"15","author":[{"given":"Penghui","family":"You","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoling","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanbing","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lihong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,24]]},"reference":[{"key":"90183_CR1","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41575-022-00704-9","volume":"20","author":"C Yang","year":"2023","unstructured":"Yang, C. et al. Evolving therapeutic landscape of advanced hepatocellular carcinoma. Nat. Rev. Gastroenterol. Hepatol. 20, 203\u2013222. https:\/\/doi.org\/10.1038\/s41575-022-00704-9 (2023).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"90183_CR2","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.ccell.2024.01.007","volume":"42","author":"X Yang","year":"2024","unstructured":"Yang, X. et al. Precision treatment in advanced hepatocellular carcinoma. Cancer Cell 42, 180\u2013197. https:\/\/doi.org\/10.1016\/j.ccell.2024.01.007 (2024).","journal-title":"Cancer Cell"},{"key":"90183_CR3","doi-asserted-by":"publisher","first-page":"9509","DOI":"10.1038\/s41598-024-59877-9","volume":"14","author":"X Gao","year":"2024","unstructured":"Gao, X. et al. Immunotherapy and drug sensitivity predictive roles of a novel prognostic model in hepatocellular carcinoma. Sci. Rep. 14, 9509. https:\/\/doi.org\/10.1038\/s41598-024-59877-9 (2024).","journal-title":"Sci. Rep."},{"key":"90183_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241210045","author":"MC Stark","year":"2023","unstructured":"Stark, M. C., Joubert, A. M. & Visagie, M. H. Molecular farming of pembrolizumab and nivolumab. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms241210045 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"90183_CR5","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1053\/j.gastro.2017.06.007","volume":"153","author":"D Sia","year":"2017","unstructured":"Sia, D. et al. Identification of an immune-specific class of hepatocellular carcinoma. Based Mol. Featur. Gastroenterol. 153, 812\u2013826. https:\/\/doi.org\/10.1053\/j.gastro.2017.06.007 (2017).","journal-title":"Based Mol. Featur. Gastroenterol."},{"key":"90183_CR6","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.3892\/ol.2020.11372","volume":"19","author":"L Li","year":"2020","unstructured":"Li, L. et al. Implications of driver genes associated with a high tumor mutation burden identified using next-generation sequencing on immunotherapy in hepatocellular carcinoma. Oncol. Lett. 19, 2739\u20132748. https:\/\/doi.org\/10.3892\/ol.2020.11372 (2020).","journal-title":"Oncol. Lett."},{"key":"90183_CR7","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","volume":"357","author":"DT Le","year":"2017","unstructured":"Le, D. T. et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357, 409\u2013413. https:\/\/doi.org\/10.1126\/science.aan6733 (2017).","journal-title":"Science"},{"key":"90183_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.107164","volume":"90","author":"B Hu","year":"2021","unstructured":"Hu, B., Yang, X. B. & Sang, X. T. Molecular subtypes based on immune-related genes predict the prognosis for hepatocellular carcinoma patients. Int. Immunopharmacol. 90, 107164. https:\/\/doi.org\/10.1016\/j.intimp.2020.107164 (2021).","journal-title":"Int. Immunopharmacol."},{"key":"90183_CR9","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12967-020-02691-4","volume":"19","author":"X Gu","year":"2021","unstructured":"Gu, X. et al. Model based on five tumour immune microenvironment-related genes for predicting hepatocellular carcinoma immunotherapy outcomes. J. Transl. Med. 19, 26. https:\/\/doi.org\/10.1186\/s12967-020-02691-4 (2021).","journal-title":"J. Transl. Med."},{"key":"90183_CR10","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1007\/s00262-020-02817-z","volume":"70","author":"M Yi","year":"2021","unstructured":"Yi, M. et al. Immune signature-based risk stratification and prediction of immune checkpoint inhibitor\u2019s efficacy for lung adenocarcinoma. Cancer Immunol. Immunother.\u202f: CII 70, 1705\u20131719. https:\/\/doi.org\/10.1007\/s00262-020-02817-z (2021).","journal-title":"Cancer Immunol. Immunother. : CII"},{"key":"90183_CR11","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical Association Declaration of Helsinki","year":"2013","unstructured":"World Medical Association Declaration of Helsinki. ethical principles for medical research involving human subjects. Jama 310, 2191\u20132194. https:\/\/doi.org\/10.1001\/jama.2013.281053 (2013).","journal-title":"Jama"},{"key":"90183_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.23469","volume":"34","author":"GZ Li","year":"2020","unstructured":"Li, G. Z., Deng, J. F., Qi, Y. Z., Liu, R. & Liu, Z. X. COLEC12 regulates apoptosis of osteosarcoma through Toll-like receptor 4-activated inflammation. J. Clin. Lab. Anal. 34, e23469. https:\/\/doi.org\/10.1002\/jcla.23469 (2020).","journal-title":"J. Clin. Lab. Anal."},{"key":"90183_CR13","doi-asserted-by":"publisher","first-page":"1198878","DOI":"10.3389\/fimmu.2023.1198878","volume":"14","author":"H Chen","year":"2023","unstructured":"Chen, H., Yang, W., Li, Y., Ma, L. & Ji, Z. Leveraging a disulfidptosis-based signature to improve the survival and drug sensitivity of bladder cancer patients. Front. Immunol. 14, 1198878. https:\/\/doi.org\/10.3389\/fimmu.2023.1198878 (2023).","journal-title":"Front. Immunol."},{"key":"90183_CR14","doi-asserted-by":"publisher","DOI":"10.1007\/s12033-024-01203-9","author":"W Shi","year":"2024","unstructured":"Shi, W., Dong, J., Zhong, B., Hu, X. & Zhao, C. Predicting the prognosis of bladder cancer patients through integrated multi-omics exploration of chemotherapy-related hypoxia genes. Mol. Biotechnol. https:\/\/doi.org\/10.1007\/s12033-024-01203-9 (2024).","journal-title":"Mol. Biotechnol."},{"key":"90183_CR15","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1186\/s12885-023-11100-0","volume":"23","author":"IK Kerzeli","year":"2023","unstructured":"Kerzeli, I. K. et al. Elevated levels of MMP12 sourced from macrophages are associated with poor prognosis in urothelial bladder cancer. BMC Cancer 23, 605. https:\/\/doi.org\/10.1186\/s12885-023-11100-0 (2023).","journal-title":"BMC Cancer"},{"key":"90183_CR16","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.15598","volume":"11","author":"W Zhang","year":"2023","unstructured":"Zhang, W. et al. MMP12 serves as an immune cell-related marker of disease status and prognosis in lung squamous cell carcinoma. PeerJ 11, e15598. https:\/\/doi.org\/10.7717\/peerj.15598 (2023).","journal-title":"PeerJ"},{"key":"90183_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2023.101040","volume":"73","author":"Z Zhang","year":"2024","unstructured":"Zhang, Z. et al. NDRG1 overcomes resistance to immunotherapy of pancreatic ductal adenocarcinoma through inhibiting ATG9A-dependent degradation of MHC-1. Drug Res. Updat.\u202f: Rev. & Comment. Antimicrob. & Anticancer Chemother. 73, 101040. https:\/\/doi.org\/10.1016\/j.drup.2023.101040 (2024).","journal-title":"Drug Res. Updat. : Rev. & Comment. Antimicrob. & Anticancer Chemother."},{"key":"90183_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202203973","volume":"10","author":"B Tang","year":"2023","unstructured":"Tang, B. et al. Targeted xCT-mediated Ferroptosis and Protumoral Polarization of Macrophages Is Effective against HCC and Enhances the Efficacy of the Anti-PD-1\/L1 Response. Adv. Sci. 10, e2203973. https:\/\/doi.org\/10.1002\/advs.202203973 (2023).","journal-title":"Adv. Sci."},{"key":"90183_CR19","doi-asserted-by":"publisher","first-page":"3405","DOI":"10.1007\/s00262-023-03516-1","volume":"72","author":"N Sauer","year":"2023","unstructured":"Sauer, N. et al. TIM-3 as a promising target for cancer immunotherapy in a wide range of tumors. Cancer Immunol. Immunothe.\u202f: CII 72, 3405\u20133425. https:\/\/doi.org\/10.1007\/s00262-023-03516-1 (2023).","journal-title":"Cancer Immunol. Immunothe. : CII"},{"key":"90183_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23179958","author":"N Sauer","year":"2022","unstructured":"Sauer, N. et al. LAG-3 as a potent target for novel anticancer therapies of a wide range of tumors. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms23179958 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"90183_CR21","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s12943-023-01885-w","volume":"22","author":"M Yi","year":"2023","unstructured":"Yi, M. et al. Exploiting innate immunity for cancer immunotherapy. Mol. Cancer 22, 187. https:\/\/doi.org\/10.1186\/s12943-023-01885-w (2023).","journal-title":"Mol. Cancer"},{"key":"90183_CR22","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12943-024-01945-9","volume":"23","author":"T Xie","year":"2024","unstructured":"Xie, T. et al. Multi-cohort validation of Ascore: an anoikis-based prognostic signature for predicting disease progression and immunotherapy response in bladder cancer. Mol. Cancer 23, 30. https:\/\/doi.org\/10.1186\/s12943-024-01945-9 (2024).","journal-title":"Mol. Cancer"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-90183-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-90183-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-90183-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T13:17:50Z","timestamp":1740403070000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-90183-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,24]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["90183"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-90183-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,24]]},"assertion":[{"value":"20 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6618"}}